Gail Boudreaux - Mar 1, 2024 Form 4 Insider Report for Elevance Health, Inc. (ELV)

Role
President and CEO, Director
Signature
/s/ Kathleen S. Kiefer, Attorney in fact
Stock symbol
ELV
Transactions as of
Mar 1, 2024
Transactions value $
-$9,610,862
Form type
4
Date filed
3/5/2024, 04:21 PM
Previous filing
Mar 10, 2023
Next filing
Mar 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELV Common Stock Tax liability -$9.61M -19.3K -14.05% $499.11 118K Mar 1, 2024 Direct F1
transaction ELV Common Stock Award $0 +8.42K +7.14% $0.00 126K Mar 1, 2024 Direct F2
transaction ELV Common Stock Award $0 +34.5K +27.35% $0.00 161K Mar 1, 2024 Direct F3, F4
holding ELV Common Stock 60 Mar 1, 2024 Shares Held in Spouse's Revocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELV Employee Stock Option (Right to Buy) Award $0 +32.5K $0.00 32.5K Mar 1, 2024 Common Stock 32.5K $499.11 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.
F2 Represents restricted share units. Restrictions lapse as follows: 2,805 shares each on 3/1/2025, 3/1/2026, and 3/1/2027.
F3 Represents performance based restricted share units. Restrictions lapse on 3/1/2024.
F4 Balance includes 392.27 shares acquired on 3/24/2023, 389.71 shares acquired on 6/23/2023 and 388.21 shares acquired on 9/23/2023 through a dividend reinvestment plan.
F5 The option represents a right to purchase a total of 32,480 shares, and is exercisable in one installment of 10,826 shares and two installments of 10,827 shares each, beginning on 3/1/2025, which is the one-year anniversary of the option grant date.